Market Size of Asia-Pacific Insulin Syringe Industry
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.04 Billion |
| Market Size (2029) | USD 1.08 Billion |
| CAGR (2024 - 2029) | 0.85 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
APAC Insulin Syringe Market Analysis
The Asia-Pacific Insulin Syringe Market size is estimated at USD 1.04 billion in 2024, and is expected to reach USD 1.08 billion by 2029, growing at a CAGR of 0.85% during the forecast period (2024-2029).
The demand for insulin syringes in the Asia-Pacific region is experiencing a notable increase, mainly due to the rising prevalence of diabetes. As the number of individuals with diabetes continues to rise, there is a growing requirement for efficient insulin delivery systems, which in turn is fueling the market for insulin syringes in the region. This article delves into the factors that are contributing to the expansion of the Asia-Pacific insulin syringe market amidst the escalating diabetes epidemic.
The Asia-Pacific region is currently facing a significant health issue with the emergence of diabetes. This problem is prevalent in countries such as China, India, Japan, and others. The rise in diabetes cases can be attributed to various factors including sedentary lifestyles, unhealthy eating habits, and genetic predisposition. The International Diabetes Federation (IDF) reports that the Asia-Pacific region has the highest number of individuals living with diabetes, making up a considerable portion of the global diabetic population.
The prevalence of diabetes in the region has led to a strong need for insulin delivery systems, such as syringes. Insulin injections are vital for managing diabetes, particularly for those with type 1 diabetes and some individuals with type 2 diabetes who rely on insulin therapy. Insulin syringes are essential for accurately administering insulin, guaranteeing the correct dosage and successful glycemic control.
Diabetes poses an emerging healthcare burden across the region. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and thus incur more healthcare expenses compared to non-diabetic people.
Furthermore, patients attempting to control their blood glucose levels tightly to prevent the long-term complications associated with fluctuations in blood glucose levels are at greater risk for overcorrection and the resultant hypoglycemia. Achieving nominal results can be very difficult without multiple daily injections of insulin or insulin pump therapy.
Owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
